AbbVie Inc (ABBV)vsBiodesix Inc (BDSX)
ABBV
AbbVie Inc
$264.53
+0.20%
HEALTHCARE · Cap: $454.36B
BDSX
Biodesix Inc
$28.43
-2.64%
HEALTHCARE · Cap: $284.51M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 62448% more annual revenue ($64.39B vs $102.94M). ABBV leads profitability with a 9.8% profit margin vs -27.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
BDSX
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.5%
Fair Value
$152.16
Current Price
$264.53
$112.37 premium
Margin of Safety
-8.5%
Fair Value
$9.54
Current Price
$28.43
$18.89 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 34.2% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 32.7x book value
ROE of -349.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : BDSX
The strongest argument for BDSX centers on Revenue Growth. Revenue growth of 34.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : BDSX
The primary concerns for BDSX are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 7.85 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while BDSX is a hypergrowth play — different risk/reward profiles.
BDSX carries more volatility with a beta of 0.59 — expect wider price swings.
BDSX is growing revenue faster at 34.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 29/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Biodesix Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?